Oculis Holding AG (OCS) Common Equity (2020 - 2026)
Oculis Holding AG (OCS) posted quarterly Common Equity of $251.1 million for Q1 2026, up 38.83% year-over-year from $180.9 million in Q1 2025, and up 2.37% quarter-over-quarter from $245.3 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Common Equity (2020 - 2026) Analysis & Trends
Oculis Holding AG's Common Equity history runs 6 years deep, the most recent figure standing at $251.1 million for Q1 2026.
- In Q1 2026, Common Equity rose 38.83% year-over-year to $251.1 million; the TTM figure through Mar 2026 stood at $251.1 million (up 38.83% YoY), while the FY2025 annual figure was $236.5 million, up 183.51% from the prior year.
- Common Equity for Q1 2026 stood at $251.1 million, up from $245.3 million in the prior quarter.
- The five-year high for Common Equity was $251.1 million in Q1 2026, with the low at -$101.7 million in Q4 2022.
- The 5-year median for Common Equity is $124.8 million (2024), against an average of $128.9 million.
- The sharpest annual moves came in 2022 and 2023: Common Equity plunged 53.87% in 2022, then surged 203.88% in 2023.
- Oculis Holding AG's Common Equity stood at -$101.7 million in 2022, then soared by 203.88% to $105.7 million in 2023, then dropped by 20.72% to $83.8 million in 2024, then jumped by 192.85% to $245.3 million in 2025, then grew by 2.37% to $251.1 million in 2026.
- Business Quant data shows OCS's Common Equity at $251.1 million in Q1 2026, $245.3 million in Q4 2025, and $163.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 277.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 277.51 Mn |
| Mar 31, 2026 | 251.12 Mn |
| Dec 31, 2025 | 245.32 Mn |
| Sep 30, 2025 | 163.26 Mn |
| Jun 30, 2025 | 172.84 Mn |
| Mar 31, 2025 | 180.88 Mn |
| Dec 31, 2024 | 83.77 Mn |
| Sep 30, 2024 | 109.91 Mn |
| Jun 30, 2024 | 124.76 Mn |
| Mar 31, 2024 | 90.55 Mn |
| Dec 31, 2023 | 105.66 Mn |
| Sep 30, 2023 | 119.56 Mn |
| Jun 30, 2023 | 130.34 Mn |
| Dec 31, 2022 | -101.72 Mn |
| Dec 31, 2021 | -66.11 Mn |
| Dec 31, 2020 | -48.29 Mn |